Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
5.34
Dollar change
-0.41
Percentage change
-7.13
%
Index- P/E- EPS (ttm)-0.93 Insider Own8.07% Shs Outstand44.68M Perf Week3.89%
Market Cap238.59M Forward P/E- EPS next Y-1.05 Insider Trans0.84% Shs Float41.07M Perf Month193.41%
Income-41.47M PEG- EPS next Q-0.25 Inst Own12.13% Short Float6.85% Perf Quarter251.32%
Sales0.49M P/S486.92 EPS this Y-4.78% Inst Trans-10.89% Short Ratio1.72 Perf Half Y233.75%
Book/sh1.56 P/B3.42 EPS next Y-8.26% ROA-41.90% Short Interest2.81M Perf Year251.32%
Cash/sh1.67 P/C3.19 EPS next 5Y- ROE-47.07% 52W Range0.94 - 6.42 Perf YTD260.81%
Dividend Est.- P/FCF- EPS past 5Y35.42% ROI-58.24% 52W High-16.82% Beta1.95
Dividend TTM- Quick Ratio7.41 Sales past 5Y9.26% Gross Margin18.44% 52W Low468.09% ATR (14)0.61
Dividend Ex-Date- Current Ratio7.41 EPS Y/Y TTM-4.47% Oper. Margin-9305.74% RSI (14)64.23 Volatility13.76% 19.11%
Employees32 Debt/Eq0.03 Sales Y/Y TTM26.42% Profit Margin-8496.93% Recom1.00 Target Price10.50
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-7.34% Payout- Rel Volume0.53 Prev Close5.75
Sales Surprise212.00% EPS Surprise21.38% Sales Q/Q21.87% EarningsFeb 29 AMC Avg Volume1.63M Price5.34
SMA2017.69% SMA5090.51% SMA200196.21% Trades Volume863,746 Change-7.13%
Date Action Analyst Rating Change Price Target Change
Jan-05-22Initiated William Blair Outperform
Dec-08-21Initiated Robert W. Baird Outperform $19
Aug-09-21Resumed Maxim Group Buy $30 → $20
Oct-22-20Initiated H.C. Wainwright Buy $27
Oct-08-20Initiated Piper Sandler Overweight $25
Mar-21-24 07:55AM
Mar-14-24 08:50AM
08:08AM
Mar-06-24 04:05PM
12:00PM
10:12AM Loading…
Mar-01-24 10:12AM
Feb-29-24 07:40PM
04:07PM
04:06PM
04:05PM
Feb-26-24 08:00AM
Feb-22-24 08:00AM
Jan-17-24 10:30AM
Nov-20-23 04:05PM
Nov-02-23 04:05PM
04:05PM Loading…
Oct-26-23 04:05PM
Oct-23-23 08:45AM
Oct-11-23 09:35AM
Sep-26-23 04:05PM
Sep-05-23 08:00AM
Aug-09-23 04:05PM
Aug-07-23 04:05PM
Jul-24-23 05:09PM
Jun-20-23 05:22PM
Jun-05-23 08:00AM
May-04-23 04:10PM
Mar-28-23 08:00AM
Mar-06-23 08:15AM
Mar-04-23 07:11AM
Mar-02-23 04:10PM
08:15AM Loading…
Feb-27-23 08:15AM
Feb-02-23 08:00AM
Jan-10-23 08:00AM
Nov-21-22 10:52AM
Nov-08-22 08:15AM
Nov-03-22 04:10PM
Sep-12-22 04:05PM
Sep-10-22 07:30AM
Sep-08-22 08:15AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-04-22 04:10PM
Jul-05-22 08:30AM
Jul-02-22 09:10AM
May-17-22 08:30AM
May-09-22 08:02AM
May-05-22 04:10PM
Apr-12-22 04:00PM
Apr-08-22 01:05PM
01:05PM
Mar-22-22 09:05AM
Mar-17-22 06:32AM
Mar-08-22 04:45PM
Mar-01-22 08:30AM
Feb-24-22 04:10PM
Feb-17-22 03:02PM
Jan-31-22 06:22PM
Jan-20-22 03:44PM
01:46PM
Jan-18-22 05:00PM
Jan-13-22 09:17AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-10-21 08:30AM
Dec-08-21 09:38AM
Dec-03-21 08:30AM
Nov-18-21 07:00AM
Nov-14-21 07:18AM
Nov-09-21 08:30AM
Nov-04-21 04:15PM
Oct-28-21 03:06PM
Sep-30-21 08:36PM
Sep-15-21 06:37AM
Sep-08-21 04:00PM
Sep-07-21 08:30AM
Aug-25-21 08:15AM
Aug-06-21 04:15AM
Aug-05-21 04:15PM
Aug-03-21 03:01PM
Jul-12-21 08:00AM
Jul-06-21 08:30AM
Jun-28-21 08:30AM
Jun-10-21 12:30PM
Jun-08-21 08:30AM
May-24-21 08:35AM
02:09AM
May-20-21 08:30AM
May-06-21 04:10PM
Apr-23-21 11:39AM
Apr-12-21 06:00AM
Apr-10-21 08:30AM
08:30AM
Apr-08-21 08:30AM
Mar-25-21 01:41AM
Mar-11-21 08:30AM
Mar-10-21 04:30PM
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PACE GARY WDirectorDec 19 '23Buy1.3730,00041,100697,761Dec 19 06:39 PM
Last Close
Mar 28 04:00PM ET
29.22
Dollar change
+0.18
Percentage change
0.62
%
PCRX Pacira BioSciences Inc daily Stock Chart
IndexRUT P/E37.67 EPS (ttm)0.78 Insider Own2.87% Shs Outstand46.48M Perf Week-0.24%
Market Cap1.36B Forward P/E8.21 EPS next Y3.56 Insider Trans-8.21% Shs Float45.16M Perf Month-2.31%
Income41.95M PEG3.62 EPS next Q0.65 Inst Own106.02% Short Float9.02% Perf Quarter-14.84%
Sales674.98M P/S2.01 EPS this Y0.08% Inst Trans2.38% Short Ratio8.02 Perf Half Y-5.86%
Book/sh18.72 P/B1.56 EPS next Y26.54% ROA2.58% Short Interest4.07M Perf Year-26.79%
Cash/sh5.99 P/C4.88 EPS next 5Y10.40% ROE5.10% 52W Range25.93 - 48.60 Perf YTD-13.40%
Dividend Est.- P/FCF9.74 EPS past 5Y- ROI2.92% 52W High-39.88% Beta0.76
Dividend TTM- Quick Ratio4.17 Sales past 5Y15.46% Gross Margin64.15% 52W Low12.69% ATR (14)1.02
Dividend Ex-Date- Current Ratio5.24 EPS Y/Y TTM155.39% Oper. Margin12.94% RSI (14)46.48 Volatility3.31% 3.70%
Employees712 Debt/Eq0.67 Sales Y/Y TTM1.22% Profit Margin6.22% Recom1.20 Target Price45.30
Option/ShortYes / Yes LT Debt/Eq0.65 EPS Q/Q316.94% Payout0.00% Rel Volume1.12 Prev Close29.04
Sales Surprise0.35% EPS Surprise0.76% Sales Q/Q5.40% EarningsFeb 29 BMO Avg Volume507.79K Price29.22
SMA20-1.52% SMA50-3.46% SMA200-10.25% Trades Volume569,631 Change0.62%
Date Action Analyst Rating Change Price Target Change
Mar-07-24Resumed JP Morgan Overweight $80 → $45
Dec-20-23Initiated Raymond James Outperform $42
Aug-03-23Upgrade TD Cowen Market Perform → Outperform $50
Jan-31-23Resumed Wedbush Outperform $88 → $60
Oct-21-22Resumed Jefferies Buy $66
Jan-03-22Resumed JP Morgan Overweight $75 → $83
Jul-26-21Upgrade JP Morgan Neutral → Overweight $75
Apr-21-21Resumed JP Morgan Neutral $70
Apr-09-21Initiated Berenberg Buy $93
Apr-07-21Resumed RBC Capital Mkts Outperform $86
Mar-14-24 08:23AM
Mar-13-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
08:38AM Loading…
Mar-01-24 08:38AM
06:05AM
12:28AM
Feb-29-24 10:00AM
09:15AM
08:32AM
08:26AM
08:00AM
Feb-22-24 08:00AM
Feb-15-24 08:36AM
08:00AM Loading…
Feb-07-24 08:00AM
Feb-01-24 10:45AM
Jan-05-24 12:21PM
Jan-04-24 05:00PM
Jan-03-24 08:00AM
Dec-21-23 07:30AM
Dec-06-23 11:13AM
Nov-13-23 10:10AM
Nov-10-23 07:30AM
Nov-07-23 08:00AM
Nov-04-23 10:28AM
Nov-02-23 12:34PM
10:00AM
08:23AM
08:00AM
08:00AM Loading…
Oct-26-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-02-23 08:00AM
Sep-27-23 12:07PM
11:50AM
Sep-26-23 04:30PM
Sep-06-23 08:00AM
Aug-03-23 10:03AM
Aug-02-23 12:45PM
08:11AM
08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jun-21-23 08:00PM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-09-23 08:00AM
May-03-23 11:42PM
05:25PM
03:11PM
08:11AM
08:00AM
Apr-26-23 08:00PM
08:00AM
Apr-20-23 09:20AM
08:00AM
Apr-19-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 11:30AM
Mar-29-23 08:00AM
Mar-27-23 08:00AM
Mar-24-23 08:50AM
Mar-22-23 08:00AM
Mar-09-23 09:17AM
Mar-08-23 08:00AM
Feb-28-23 11:39PM
08:00AM
Feb-23-23 08:00AM
Feb-21-23 08:00AM
Jan-05-23 04:30PM
Jan-04-23 08:00AM
Dec-20-22 10:06AM
Dec-13-22 08:00AM
Nov-18-22 01:38PM
Nov-17-22 08:05AM
Nov-14-22 08:00AM
Nov-09-22 05:14AM
Nov-08-22 08:00AM
Nov-04-22 10:54AM
Nov-03-22 09:15AM
08:00AM
Nov-01-22 10:01AM
Oct-27-22 10:02AM
Oct-20-22 08:00AM
Oct-15-22 08:34AM
Oct-13-22 08:00AM
Oct-07-22 02:10PM
Sep-27-22 08:00AM
Sep-21-22 06:04PM
10:08AM
08:00AM
Sep-20-22 08:00AM
Sep-13-22 08:00AM
Sep-08-22 10:42AM
Sep-07-22 11:07AM
07:00AM
Sep-02-22 11:31AM
Aug-10-22 08:00AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PACE GARY WDirectorMar 08 '24Sale30.6090,0002,754,00022,127Mar 08 05:33 PM
PACE GARY WDirectorMar 07 '24Sale30.8128,257870,598112,127Mar 08 05:33 PM
PACE GARY WDirectorMar 06 '24Sale29.671,06631,628140,384Mar 08 05:33 PM
WINSTON ROYChief Medical OfficerAug 02 '23Sale34.8850917,75152,440Aug 04 04:47 PM
Riker Lauren BullaroSenior Vice President, FinanceJul 05 '23Sale38.9164325,01922,687Jul 07 08:04 PM
Riker Lauren BullaroSenior Vice President, FinanceJun 14 '23Sale38.426,366244,60622,687Jun 16 05:39 PM
Williams Kristen MarieChief Administrative OfficerJun 14 '23Sale37.036,467239,47325,375Jun 16 05:42 PM
Kronenfeld Mark A.DirectorJun 08 '23Option Exercise29.9015,000448,50032,897Jun 12 04:16 PM
Kronenfeld Mark A.DirectorJun 08 '23Sale37.0415,000555,60017,897Jun 12 04:16 PM
STACK DAVID MCEO and ChairmanJun 07 '23Sale37.875,326201,669153,781Jun 07 09:33 PM
WINSTON ROYChief Medical OfficerJun 07 '23Sale37.871,85770,31541,356Jun 07 09:36 PM
Reinhart Charles A. IIIChief Financial OfficerJun 07 '23Sale37.871,37151,91333,626Jun 07 09:29 PM
Williams Kristen MarieChief Administrative OfficerJun 07 '23Sale37.871,35751,38320,892Jun 07 09:34 PM
Ellis Ronald J. Jr.Chief Strategy OfficerJun 07 '23Sale37.871,16243,99930,909Jun 07 09:20 PM
REINHARDT MAXPresident, Rest of WorldJun 07 '23Sale37.871,09941,61429,225Jun 07 09:28 PM
McLoughlin DennisChief Customer OfficerJun 07 '23Sale37.871,05740,02338,115Jun 07 09:24 PM
GAUGLER DARYLChief Operating OfficerJun 07 '23Sale37.871,04739,64521,539Jun 07 09:22 PM
Riker Lauren BullaroSenior Vice President, FinanceJun 07 '23Sale37.8761623,32519,053Jun 07 09:31 PM
SLONIN JONATHANChief Clinical OfficerJun 07 '23Sale37.8749018,55436,323Jun 07 09:32 PM
STACK DAVID MCEO and ChairmanJun 06 '23Sale38.995,058197,216159,107Jun 07 09:33 PM
MOLLOY ANTHONYChief Lgl & Compliance OfficerJun 06 '23Sale38.554,521174,28512,877Jun 07 09:26 PM
WINSTON ROYChief Medical OfficerJun 06 '23Sale38.991,77969,36543,213Jun 07 09:36 PM
Williams Kristen MarieChief Administrative OfficerJun 06 '23Sale38.991,30150,72722,249Jun 07 09:34 PM
Reinhart Charles A. IIIChief Financial OfficerJun 06 '23Sale38.991,23648,19334,997Jun 07 09:29 PM
Ellis Ronald J. Jr.Chief Strategy OfficerJun 06 '23Sale38.991,11443,43632,071Jun 07 09:20 PM
REINHARDT MAXPresident, Rest of WorldJun 06 '23Sale38.991,05441,09730,324Jun 07 09:28 PM
McLoughlin DennisChief Customer OfficerJun 06 '23Sale38.991,01439,53739,172Jun 07 09:24 PM
GAUGLER DARYLChief Operating OfficerJun 06 '23Sale38.991,00539,18622,586Jun 07 09:22 PM
Riker Lauren BullaroSenior Vice President, FinanceJun 06 '23Sale38.9959123,04419,669Jun 07 09:31 PM
SLONIN JONATHANChief Clinical OfficerJun 06 '23Sale38.9947118,36536,813Jun 07 09:32 PM
MOLLOY ANTHONYChief Lgl & Compliance OfficerJun 05 '23Sale38.282,26786,77417,398Jun 07 09:26 PM
GAUGLER DARYLChief Operating OfficerJun 05 '23Sale38.741,00038,74023,591Jun 07 09:22 PM
Brege LauraDirectorJun 05 '23Sale38.7460023,2449,547Jun 07 09:18 PM
HASTINGS PAUL JDirectorJun 05 '23Sale38.3458022,2376,599Jun 07 09:23 PM
GAUGLER DARYLChief Operating OfficerMay 31 '23Option Exercise34.002,50085,00026,894Jun 02 06:28 PM
GAUGLER DARYLChief Operating OfficerMay 31 '23Sale39.082,50097,70024,591Jun 02 06:28 PM
HASTINGS PAUL JDirectorMay 15 '23Option Exercise29.907,000209,30014,179May 17 04:07 PM
HASTINGS PAUL JDirectorMay 15 '23Sale41.857,000292,9507,179May 17 04:07 PM
PACE GARY WDirectorMay 11 '23Option Exercise29.907,000209,300144,690May 15 06:53 PM
PACE GARY WDirectorMay 11 '23Sale41.785,015209,527139,675May 15 06:53 PM
Brege LauraDirectorApr 03 '23Option Exercise29.907,000209,30017,147Apr 05 04:34 PM
Brege LauraDirectorApr 03 '23Sale40.727,000285,04010,147Apr 05 04:34 PM